Çanakçı, F.GülfeşanEr, NilayDuygu, GoncaVarol, G.Füsun2023-04-202023-04-2020222468-7855https://doi.org/10.1016/j.jormas.2021.09.011https://hdl.handle.net/20.500.11776/11066Medication-related osteonecrosis of the jaw (MRONJ) is a drug adverse reaction. Seven osteonecrosis areas in 5 cases were treated with stage-2 MRONJ using human amniotic membrane (HAM) transplantation after sequestrectomy. Patients were evaluated in terms of infection (pain, erythema, and pus), mucosal coverage, and pain at 1, 2, 4, 8, and 12 weeks. Patients who showed improvement (total mucosal coverage, no sign of infection and pain) at the end of 12 weeks were followed up every 8 weeks. Also, radiographic examinations (panoramic radiography at every 8 weeks, cone-beam computed tomography at every 6 months) were performed to evaluate bone destruction. Complete mucosal closure was achieved in 6 necrosis sites. In only 1 patient, mucosal coverage was not achieved. No pain and infection relapse were observed during the follow-ups. HAM might be an effective material in terms of soft tissue healing and elimination of pain and infection for stage-2 MRONJ. Clinical Trials Registration Number: NCT04967963 © 2021en10.1016/j.jormas.2021.09.011info:eu-repo/semantics/closedAccessAmniotic membraneBisphosphonatesMedication-related osteonecrosis of the jawMRONJMucosal coveragebone density conservation agentamnioncase reporthumanjaw osteonecrosispainpanoramic radiographyAmnionBisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsHumansPainRadiography, PanoramicArticle1233e28e31Q3WOS:0008836905000052-s2.0-8512990845034563730Q2